Treatment of chronic obstructive pulmonary disease: Combination or component therapy?

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 10, 2003, Pages 1296-1297

  Hackam, Daniel G ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; SALMETEROL;

ADULT; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; NOTE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038626704     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113(1):59-65.
2. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155(4):1283-9.
3. Calverley PM. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J Suppl 2001;34:60s-66s.
4. Gomez FP, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002;8(2):81-6.